Boston Family Office LLC Sells 503 Shares of Pfizer Inc. (NYSE:PFE)

Boston Family Office LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 67,342 shares of the biopharmaceutical company’s stock after selling 503 shares during the quarter. Boston Family Office LLC’s holdings in Pfizer were worth $1,706,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter valued at $27,000. North Capital Inc. purchased a new position in Pfizer during the 1st quarter worth $28,000. Finally, Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter worth $28,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on PFE shares. Redburn Atlantic lowered their target price on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. TD Cowen reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research report on Tuesday, April 22nd. The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research boosted their target price on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. Finally, Leerink Partners decreased their price target on Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Performance

Shares of PFE opened at $25.16 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s fifty day moving average price is $24.60 and its two-hundred day moving average price is $24.44. The firm has a market cap of $143.05 billion, a PE ratio of 13.38, a PEG ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm posted $0.60 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.